The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections - PubMed (original) (raw)

Review

The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections

James A Driscoll et al. Drugs. 2007.

Abstract

Pseudomonas aeruginosa is an important bacterial pathogen, particularly as a cause of infections in hospitalised patients, immunocompromised hosts and patients with cystic fibrosis. Surveillance of nosocomial P. aeruginosa infections has revealed trends of increasing antimicrobial resistance, including carbapenem resistance and multidrug resistance. Mechanisms of antimicrobial resistance include multidrug efflux pumps, ss-lactamases and downregulation of outer membrane porins. Mechanisms of virulence include secreted toxins and the ability to form biofilms. The effective treatment of infections caused by P. aeruginosa includes prevention when possible, source control measures as necessary and prompt administration of appropriate antibacterial agents. Antibacterial de-escalation should be pursued in patients with an appropriate clinical response, especially when antibacterial susceptibilities are known. Multidrug-resistant P. aeruginosa may require treatment with less commonly used antibacterials (e.g. colistin), but newer anti-pseudomonal antibacterials are expected to be available in the near future.

PubMed Disclaimer

Similar articles

• The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update.
  Reynolds D, Kollef M. Reynolds D, et al. Drugs. 2021 Dec;81(18):2117-2131. doi: 10.1007/s40265-021-01635-6. Epub 2021 Nov 7. Drugs. 2021. PMID: 34743315 Free PMC article. Review.
• Epidemiological, Physiological, and Molecular Characteristics of a Brazilian Collection of Carbapenem-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
  Dias VC, Resende JA, Bastos AN, De Andrade Bastos LQ, De Andrade Bastos VQ, Bastos RV, Diniz CG, Da Silva VL. Dias VC, et al. Microb Drug Resist. 2017 Oct;23(7):852-863. doi: 10.1089/mdr.2016.0219. Epub 2017 Feb 24. Microb Drug Resist. 2017. PMID: 28437232
• Current therapies for pseudomonas aeruginosa.
  Giamarellou H, Kanellakopoulou K. Giamarellou H, et al. Crit Care Clin. 2008 Apr;24(2):261-78, viii. doi: 10.1016/j.ccc.2007.12.004. Crit Care Clin. 2008. PMID: 18361945 Review.
• The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
  Banerjee D, Stableforth D. Banerjee D, et al. Drugs. 2000 Nov;60(5):1053-64. doi: 10.2165/00003495-200060050-00006. Drugs. 2000. PMID: 11129122 Review.
• Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies.
  El Zowalaty ME, Al Thani AA, Webster TJ, El Zowalaty AE, Schweizer HP, Nasrallah GK, Marei HE, Ashour HM. El Zowalaty ME, et al. Future Microbiol. 2015;10(10):1683-706. doi: 10.2217/fmb.15.48. Epub 2015 Oct 6. Future Microbiol. 2015. PMID: 26439366 Review.

Cited by

• Malonate is relevant to the lung environment and induces genome-wide stress responses in Pseudomonas aeruginosa.
  Bisht K, Elmassry MM, Mahmud HA, Bhattacharjee S, Deonarine A, Black C, Francisco MJS, Hamood AN, Wakeman CA. Bisht K, et al. Res Sq [Preprint]. 2024 Sep 10:rs.3.rs-4870062. doi: 10.21203/rs.3.rs-4870062/v1. Res Sq. 2024. PMID: 39315254 Free PMC article. Preprint.
• Structure of the type III secretion effector protein ExoU in complex with its chaperone SpcU.
  Halavaty AS, Borek D, Tyson GH, Veesenmeyer JL, Shuvalova L, Minasov G, Otwinowski Z, Hauser AR, Anderson WF. Halavaty AS, et al. PLoS One. 2012;7(11):e49388. doi: 10.1371/journal.pone.0049388. Epub 2012 Nov 14. PLoS One. 2012. PMID: 23166655 Free PMC article.
• Electrochemical Detection of Pseudomonas aeruginosa Quorum Sensing Molecule (S)-_N_-Butyryl Homoserine Lactone Using Molecularly Imprinted Polymers.
  Frigoli M, Lowdon JW, Donetti N, Crapnell RD, Banks CE, Cleij TJ, Diliën H, Eersels K, van Grinsven B. Frigoli M, et al. ACS Omega. 2024 Aug 14;9(34):36411-36420. doi: 10.1021/acsomega.4c03970. eCollection 2024 Aug 27. ACS Omega. 2024. PMID: 39220512 Free PMC article.
• Quorum Quenching Lactonase Strengthens Bacteriophage and Antibiotic Arsenal Against Pseudomonas aeruginosa Clinical Isolates.
  Mion S, Rémy B, Plener L, Brégeon F, Chabrière E, Daudé D. Mion S, et al. Front Microbiol. 2019 Sep 3;10:2049. doi: 10.3389/fmicb.2019.02049. eCollection 2019. Front Microbiol. 2019. PMID: 31551983 Free PMC article.
• Estimating Factors Related to Fluoroquinolone Resistance Based on One Health Perspective: Static and Dynamic Panel Data Analyses From Europe.
  Zhang D, Cui Y, Zhang X. Zhang D, et al. Front Pharmacol. 2019 Oct 3;10:1145. doi: 10.3389/fphar.2019.01145. eCollection 2019. Front Pharmacol. 2019. PMID: 31636561 Free PMC article.

References

1. 1. J Diabetes Complications. 2005 May-Jun;19(3):138-41 - PubMed
2. 1. BMC Infect Dis. 2005 Jan 10;5:1 - PubMed
3. 1. Am J Infect Control. 2002 Dec;30(8):476-89 - PubMed
4. 1. Clin Infect Dis. 2003 Dec 1;37(11):e154-60 - PubMed
5. 1. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1209-23 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information